Double trouble for cancer patients.

Published on Jun 14, 2021in European Heart Journal22.673
· DOI :10.1093/EURHEARTJ/EHAB252
Alexander T. Cohen59
Estimated H-index: 59
('KCL': King's College London),
Alexander T. Cohen41
Estimated H-index: 41
('KCL': King's College London),
Ingrid M. Bistervels6
Estimated H-index: 6
(UvA: University of Amsterdam)
📖 Papers frequently viewed together
#1Ella Grilz (Medical University of Vienna)H-Index: 7
#2Florian Posch (Medical University of Vienna)H-Index: 20
Last. Cihan Ay (Medical University of Vienna)H-Index: 48
view all 9 authors...
AIMS An interrelation between cancer and thrombosis is known, but population-based studies on the risk of both arterial thromboembolism (ATE) and venous thromboembolism (VTE) have not been performed. METHODS AND RESULTS International Classification of Disease 10th Revision (ICD-10) diagnosis codes of all publicly insured persons in Austria (0-90 years) were extracted from the Austrian Association of Social Security Providers dataset covering the years 2006-07 (n = 8 306 244). Patients with a his...
4 CitationsSource
#1Frits I. Mulder (AU: Aarhus University)H-Index: 6
#2Erzsébet Horváth-Puhó (Aarhus University Hospital)H-Index: 32
Last. Henrik Toft Sørensen (Aarhus University Hospital)H-Index: 146
view all 9 authors...
The incidence of venous thromboembolism in cancer patients may have changed in the past decade, possibly due to novel cancer therapies, improved survival, and high-resolution imaging. Danish medical registries were used to identify 499,092 patients with a first-time cancer diagnosis between 1997 and 2017, who were matched to 1,497,276 comparison individuals without cancer from the general population. We computed cumulative incidences of venous thromboembolism 6 and 12 months after the diagnosis/...
9 CitationsSource
#1Alok A. Khorana (Cleveland Clinic)H-Index: 67
#2Alexander T. Cohen ('KCL': King's College London)H-Index: 59
Last. Philip S. Wells (Ottawa Hospital Research Institute)H-Index: 103
view all 7 authors...
Patients with cancer are at high risk of venous thromboembolic events, and this risk can be further increased in patients with certain cancer types and by cancer treatments. Guidelines on the prevention of cancer-associated thrombosis (CAT) recommend thromboprophylaxis for hospitalised patients; however, this is not routinely recommended for ambulatory patients receiving chemotherapy and is limited to specified high-risk patients. Identification of the ambulatory patients at risk of CAT who woul...
2 CitationsSource
#1Tiziano BarbuiH-Index: 105
#2Valerio De Stefano (UCSC: Catholic University of the Sacred Heart)H-Index: 46
Last. Giovanni BarosiH-Index: 80
view all 8 authors...
This article presents the results of a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs (UCNs) in the management of thrombotic risk and thrombotic events associated with Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs). With the Delphi technique, the challenges in Ph-neg MPN-associated thrombosis were selected. The most clinically relevant UCNs resulted in: (1) providing evidence of the benefits and risks of direct oral anti...
10 CitationsSource
#1Elena Campello (UNIPD: University of Padua)H-Index: 20
#2Anton Ilich (UNC: University of North Carolina at Chapel Hill)H-Index: 7
Last. Nigel S. Key (UNC: University of North Carolina at Chapel Hill)H-Index: 78
view all 4 authors...
It has long been recognised that pancreatic cancer induces a hypercoagulable state that may lead to clinically apparent thrombosis. Although the relationship between pancreatic cancer and hypercoagulability is well described, the underlying pathological mechanism(s) and the interplay between these pathways remain a matter of intensive study. This review summarises existing data on epidemiology and pathogenesis of thrombotic complications in pancreatic cancer with a particular emphasis on novel p...
19 CitationsSource
#1Ella Grilz (Medical University of Vienna)H-Index: 7
#2Oliver Königsbrügge (Medical University of Vienna)H-Index: 13
Last. Cihan Ay (Medical University of Vienna)H-Index: 48
view all 8 authors...
In contrast to venous thromboembolism, little is known about arterial thromboembolism in patients with cancer. The aim of this study was to quantify the risk and explore clinical risk factors of arterial thromboembolism in patients with cancer, and investigate its potential impact on mortality. Patients with newly-diagnosed cancer or progression of disease after remission were included in a prospective observational cohort study and followed for 2 years. Between October 2003 and October 2013, 18...
39 CitationsSource
#1Babak B. Navi (Cornell University)H-Index: 30
#2Costantino Iadecola (Cornell University)H-Index: 119
: Currently 1 in 10 patients with ischemic stroke have comorbid cancer, and this frequency is expected to increase with continued advances in cancer therapeutics prolonging median survival. Well known for its association with venous thrombosis, cancer has recently emerged as a significant risk factor for arterial thromboembolism, including stroke; however, the underlying mechanisms are uncertain. In addition, the optimal strategies to prevent and acutely treat stroke in cancer patients are yet t...
64 CitationsSource
#1Mirela Tuzovic (UCLA: University of California, Los Angeles)H-Index: 6
#2Joerg Herrmann (Mayo Clinic)H-Index: 58
Last. Eric H. Yang (UCLA: University of California, Los Angeles)H-Index: 16
view all 6 authors...
Purpose of review Cancer is a common cause of morbidity and mortality in the USA. While the association between venous thrombosis and malignancy is well established, arterial thrombosis has more recently been recognized as a serious complication of cancer and certain chemotherapeutic agents. This review aims to summarize the most recent literature regarding the incidence and risk factors for cancer-related arterial thrombosis, understand the pathophysiologic mechanisms of thrombosis, and highlig...
27 CitationsSource
#1Malin Hultcrantz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 20
#2Magnus Björkholm (Karolinska University Hospital)H-Index: 79
Last. Therese M.-L. Andersson (KI: Karolinska Institutet)H-Index: 35
view all 7 authors...
Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at increased risk for thrombotic events. However, no population-based study has estimated this excess risk compared with matched control participants. Objective: To assess risk for arterial and venous thrombosis in patients with MPNs compared with matched control participants. Design: Matched cohort study. Setting: Population-based setting in Sweden from 1987 to 2009, with follow-up to 2010. Patients: 9429 patients ...
71 CitationsSource
#1Babak B. NaviH-Index: 30
#2Anne S. Reiner (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 35
Last. Lisa M. DeAngelisH-Index: 108
view all 8 authors...
Abstract Background The risk of arterial thromboembolism in patients with cancer is incompletely understood. Objectives The authors aimed to better define this epidemiological relationship, including the effects of cancer stage. Methods Using the Surveillance Epidemiology and End Results–Medicare linked database, the authors identified patients with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011. The...
212 CitationsSource
Cited By1